Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation
1 clinical trials · Condition
◉ Watch Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation
| Record | Firm | Date |
|---|---|---|
| Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer (NCT06970353) | Fudan University | 2025-05-27 |
Track Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation automatically
Every clearance here is in the API, with alerts when new ones post.